Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 150

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Faecal microbiota transplant for recurrent Clostridioides difficile infectionMTG71
Brolucizumab for treating diabetic macular oedemaTA820
iFuse for treating chronic sacroiliac joint painMTG39
Contrast-enhanced spectral mammography for breast cancerMIB304
Differential target multiplexed spinal cord stimulation for chronic lower back and leg painMIB305
Focal resurfacing implants to treat articular cartilage damage in the kneeIPG734
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceIPG735
Superficial venous arterialisation for chronic limb threatening ischaemiaIPG736
Avalglucosidase alfa for treating Pompe diseaseTA821
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsHTE2
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsHTE1
Type 1 diabetes in adults: diagnosis and managementNG17
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
SecurAcath for securing percutaneous cathetersMTG34
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Stockholm3 for prostate cancer screeningMIB303
Bioresorbable stent implantation to treat coronary artery diseaseIPG732
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissectionIPG733
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
PLGF-based testing to help diagnose suspected preterm pre-eclampsiaDG49

Results per page

  1. 10
  2. 25
  3. 50
  4. All